tagatosazine: RN given refers ot (D-lyxo)-isomer; RN for cpd without isomeric designation not available 6/89 [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
| ID Source | ID |
|---|---|
| PubMed CID | 166770 |
| SCHEMBL ID | 6741377 |
| MeSH ID | M0068738 |
| Synonym |
|---|
| 13121-64-7 |
| tagatosazine |
| (1r,2r,3r)-1-[5-[(1r,2r,3r)-1,2,3,4-tetrahydroxybutyl]pyrazin-2-yl]butane-1,2,3,4-tetrol |
| 2,5-bis-(d-lyxotetrahydroxybutyl)pyrazine |
| 1,2,3,4-butanetetrol, 1,1'-(2,5-pyrazinediyl)bis-, (1r-(1r*,1'r*,2r*,2'r*,3s*,3's*))- |
| SCHEMBL6741377 |
| 1,1'-(pyrazine-2,5-diyl)di(butane-1,2,3,4-tetrol) |
| DTXSID80927125 |
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 1 (11.11) | 18.7374 |
| 1990's | 1 (11.11) | 18.2507 |
| 2000's | 1 (11.11) | 29.6817 |
| 2010's | 5 (55.56) | 24.3611 |
| 2020's | 1 (11.11) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (13.03) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 9 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||